INFU InfuSystem Holdings, Inc
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1337013 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.4%
TTM net income YoY70.9%
TTM EPS YoY69.2%
Revenue 3-yr CAGR5.5%
Net income 3-yr CAGR118.3%
Margins
Gross margin57.6%
Operating margin9.8%
Net margin6.5%
FCF margin17.1%
EBITDA margin18.8%
Returns
ROE15.8%
ROA9.3%
ROIC (approx.)13.4%
Asset turnover1.42x
Leverage & solvency
Liabilities / assets38.6%
Debt / equity0.31x
Current ratio2.68x
Interest coverage13.83x
Cash quality & payout
Operating cash flow / net income2.67x
Accruals ratio-15.5%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37.59M | $36.93M | $33.68M | $36.23M | $36.49M | $36.00M | $34.72M | $33.85M |
| Cost of revenue | $15.86M | $15.52M | $14.00M | $15.79M | $15.67M | $16.13M | $15.55M | $15.63M |
| Gross profit | $21.73M | $21.41M | $19.68M | $20.43M | $20.82M | $19.87M | $19.17M | $18.22M |
| SG&A expense | $14.11M | $14.10M | $14.80M | $14.08M | $14.43M | $13.15M | $15.32M | $13.21M |
| Operating income | $4.75M | $4.15M | $1.59M | $3.71M | $3.81M | $3.78M | $618,000 | $2.62M |
| Interest expense | $257,000 | $255,000 | $255,000 | $260,000 | $330,000 | $373,000 | $336,000 | $361,000 |
| Pretax income | $4.54M | $3.87M | $1.42M | $3.50M | $3.43M | $3.45M | $253,000 | $2.26M |
| Income tax | $1.39M | $640,000 | $400,000 | $1.46M | $1.17M | $847,000 | $520,000 | $1.33M |
| Net income | $3.16M | $3.23M | $1.02M | $2.04M | $2.26M | $2.60M | -$267,000 | $933,000 |
| EBITDA | $7.87M | $7.33M | $4.84M | $7.06M | $7.09M | $7.12M | $3.94M | $6.04M |
| EPS (basic) | 0.16 | 0.16 | 0.05 | — | 0.11 | 0.12 | -0.01 | — |
| EPS (diluted) | 0.15 | 0.15 | 0.05 | — | 0.11 | 0.12 | -0.01 | — |
| Weighted avg. shares (diluted) | 21.07M | 20.92M | 20.89M | — | 20.95M | 21.06M | 21.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.11M | $964,000 | $2.11M | $3.19M | $955,000 | $720,000 | $1.51M | $527,000 |
| Receivables | $29.55M | $27.20M | $23.98M | $22.90M | $24.31M | $24.48M | $23.89M | $21.20M |
| Inventory | $5.15M | $5.52M | $5.83M | $5.39M | $5.59M | $5.67M | $6.09M | $6.53M |
| Current assets | $47.91M | $38.27M | $36.66M | $36.34M | $35.57M | $34.80M | $35.32M | $32.16M |
| PP&E, net | $2.75M | $3.00M | $3.22M | $3.36M | $3.65M | $3.81M | $3.92M | $4.03M |
| Goodwill | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M | $3.71M |
| Intangibles | $6.32M | $6.48M | $6.66M | $6.87M | $7.08M | $7.15M | $6.21M | $6.46M |
| Total assets | $104.52M | $97.70M | $98.66M | $100.56M | $98.88M | $100.85M | $104.28M | $103.61M |
| Current liabilities | $17.87M | $15.30M | $17.14M | $20.18M | $18.72M | $15.86M | $15.97M | $17.66M |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term debt | $19.69M | $20.42M | $19.65M | $19.62M | $20.93M | $26.35M | $28.71M | $23.86M |
| Total debt | $19.69M | $20.42M | $19.65M | $19.62M | $20.93M | $26.35M | $28.71M | $23.86M |
| Total liabilities | $40.37M | $38.55M | $39.91M | $43.23M | $43.41M | $46.31M | $49.13M | $46.09M |
| Shareholders' equity | $64.15M | $59.15M | $58.75M | $57.33M | $55.47M | $54.53M | $55.15M | $57.53M |
| Net debt | $10.58M | $19.46M | $17.54M | $16.44M | $19.98M | $25.63M | $27.20M | $23.34M |
| Shares outstanding | 20.03M | 19.91M | 20.18M | 20.21M | 20.33M | 20.43M | 20.97M | 21.27M |
| Cash flow statement | ||||||||
| Operating cash flow | $10.34M | $6.78M | $970,000 | $7.13M | $8.49M | $7.01M | $1.78M | $7.93M |
| Capital expenditure | $73,000 | $91,000 | $157,000 | $133,000 | $79,000 | $217,000 | $131,000 | $530,000 |
| Free cash flow | $10.27M | $6.69M | $813,000 | $6.99M | $8.41M | $6.79M | $1.65M | $7.40M |
| Investing cash flow | -$1.97M | -$4.52M | -$1.26M | -$2.19M | -$252,000 | -$1.69M | -$2.66M | -$3.27M |
| Financing cash flow | -$230,000 | -$3.40M | -$790,000 | -$2.70M | -$8.01M | -$6.11M | $1.86M | -$4.51M |
| Depreciation & amortization | $3.12M | $3.17M | $3.25M | $3.35M | $3.28M | $3.34M | $3.32M | $3.42M |
| Stock-based compensation | $1.24M | $1.24M | $1.23M | $1.27M | $1.32M | $661,000 | $1.11M | $1.18M |
| Share buybacks | $605,000 | $3.55M | $809,000 | $1.31M | $2.17M | $3.50M | $2.90M | $199,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.